Show simple item record

dc.contributor.authorSritharan, K
dc.contributor.authorRieu, R
dc.contributor.authorTree, A
dc.date.accessioned2021-05-25T11:38:31Z
dc.date.available2021-05-25T11:38:31Z
dc.date.issued2021-03-15
dc.identifier.citationAnnals of palliative medicine, 2021
dc.identifier.issn2224-5820
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4576
dc.identifier.eissn2224-5839
dc.identifier.eissn2224-5839en_US
dc.identifier.doi10.21037/apm-20-1215
dc.identifier.doi10.21037/apm-20-1215en_US
dc.description.abstractThere has been growing interest in oligometastatic prostate cancer (OMPC) with a mounting body of evidence to suggest that it is a distinct disease state, both biologically and prognostically, when compared to polymetastatic prostate cancer. Three subgroups have been recognised; de novo synchronous, metachronous/oligorecurrent and oligoprogressive disease. The belief that patients with OMPC can be treated more aggressively to improve survival is transforming patient care. Identifying these patients poses the first challenge, and we explore the imaging modalities currently utilised and those that are promising. For patients with de novo synchronous OMPC, both early systemic treatment in addition to androgen deprivation therapy (ADT) and radiotherapy to the prostate increase overall survival (OS), and both are increasingly being integrated into routine clinical practice. Metastasis-directed therapy (MDT) has predominantly been delivered using stereotactic body radiotherapy (SBRT) in prostate cancer and studies have shown SBRT is well-tolerated, provides excellent local control and can be used to delay ADT in the metachronous setting. We discuss the current management strategies in OMPC, review the evidence supporting the use of SBRT and outline ongoing trials.
dc.formatPrint-Electronic
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.titleA narrative review of oligometastatic prostate cancer-an evolving paradigm.
dc.typeJournal Article
dcterms.dateAccepted2021-02-19
rioxxterms.versionVoR
rioxxterms.versionofrecord10.21037/apm-20-1215
rioxxterms.licenseref.startdate2021-03-15
rioxxterms.licenseref.startdate2021-03-15en_US
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfAnnals of palliative medicine
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Uro-oncology Clinical Trials
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Uro-oncology Clinical Trials
pubs.publication-statusPublished
pubs.embargo.termsNot known
icr.researchteamUro-oncology Clinical Trials
icr.researchteamUro-oncology Clinical Trialsen_US
dc.contributor.icrauthorSritharan, Kobikaen
dc.contributor.icrauthorTree, Alisonen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/